SV BR 1 GM cancer vaccine - BriaCell Therapeutics

Drug Profile

SV BR 1 GM cancer vaccine - BriaCell Therapeutics

Alternative Names: Allogeneic GM CSF secreting breast cancer vaccine - BriaCell Therapeutics; BriaVax; GM CSF gene-transfected breast cancer vaccine - BriaCell Therapeutics

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Wiseman Research Initiatives LLC
  • Developer BriaCell Therapeutics Corp; Saint Vincent Catholic Medical Centers; Wiseman Research Initiatives LLC
  • Class Cancer vaccines; Gene therapies; Immunotherapies
  • Mechanism of Action Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Ovarian cancer

Most Recent Events

  • 15 Mar 2017 BriaCell Therapeutics initiates enrolment in a phase I/II trial for Breast cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater, Recurrent) in USA (NCT03066947)
  • 05 Jan 2017 BriaCell plans a clinical trial for Cancer (Combination therapy) in USA
  • 29 Mar 2016 The US FDA approves IND application for a phase IIa trial of SV BR 1 GM cancer vaccine in Breast cancer and other cancers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top